ANGIOTAX-PLUS trial: A randomized phase II trial assessing the activity of weekly paclitaxel (WP) plus or minus bevacizumab (B) in advanced angiosarcoma (AS).-Reference-Cited by-同舟云学术

ANGIOTAX-PLUS trial: A randomized phase II trial assessing the activity of weekly paclitaxel (WP) plus or minus bevacizumab (B) in advanced angiosarcoma (AS).

Published:2014-05-20 Issue:15_suppl Volume:32 Page:10501-10501
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Penel Nicolas¹,Blay Jean-Yves²,Mir Olivier³,Tresch Emmanuelle¹,Bompas Emmanuelle⁴,Domont Julien³,Cassier Philippe Alexandre²,Rolland Frederic⁵,Piperno-Neumann Sophie⁶,Italiano Antoine⁷,Chevreau Christine⁸,Cupissol Didier⁹,Bay Jacques-Olivier¹⁰,Collard Olivier¹¹,Saada Esma¹²,Bertucci François¹³,Isambert Nicolas¹⁴,Delcambre Corinne¹⁵,Clisant Stephanie¹,Ray-Coquard Isabelle Laure²,

Affiliation:

1. Centre Oscar Lambret, Lille, France

2. Centre Léon Bérard, Lyon, France

3. Institut Gustave Roussy, Villejuif, France

4. Department of Medical Oncology - Centre René Gauducheau, Nantes St Herblain, France

5. Centre René Gauducheau, Saint-Herblain, France

6. Institut Curie, Paris, France

7. Institut Bergonié, Bordeaux, France

8. Institut Claudius Regaud, Toulouse, France

9. Department of Medical Oncology, Centre Val d'Aurelle Paul Lamarque, Montpellier, France

10. Centre Jean Perrin and Centre Hospitalier Universitaire Clermont-Ferrand, Clermont-Ferrand, France

11. Institut de Cancérologie de la Loire, St. Priest en Jarez, France